Dominant Negative Effectors of Heparin Affin Regulatory Peptide (HARP) Angiogenic and Transforming Activities
Open Access
- 1 August 2002
- journal article
- Published by Elsevier BV
- Vol. 277 (35), 32071-32077
- https://doi.org/10.1074/jbc.m202747200
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- New paradigms for the treatment of cancer: The role of anti-angiogenesis agentsAdvances in Cancer Research, 2000
- Relationship Between Serum Concentrations of the Growth Factor Pleiotrophin and Pleiotrophin-Positive TumorsJNCI Journal of the National Cancer Institute, 1998
- Involvement of Receptor-like Protein Tyrosine Phosphatase ζ/RPTPβ and Its Ligand Pleiotrophin/Heparin-binding Growth-associated Molecule (HB-GAM) in Neuronal MigrationThe Journal of cell biology, 1998
- Differential expression and biological activity of the heparin-binding growth-associated molecule (HB-GAM) in lung cancer cell linesInternational Journal of Cancer, 1997
- Expression of midkine and pleiotropin in ovarian tumorsObstetrics & Gynecology, 1997
- Biochemical and mitogenic properties of the heparin-binding growth factor HARPProgress in Growth Factor Research, 1995
- Pleiotrophin transforms NIH 3T3 cells and induces tumors in nude mice.Proceedings of the National Academy of Sciences of the United States of America, 1993
- Cellular distribution of the new growth factor Pleiotrophin (HB-GAM) mRNA in developing and adult rat tissuesBrain Structure and Function, 1992
- Mitogenic properties of a new endothelial cell growth factor related to pleiotrophinBiochemical and Biophysical Research Communications, 1991
- Cloning and Expression of a Developmentally Regulated Protein That Induces Mitogenic and Neurite Outgrowth ActivityScience, 1990